CRDL
Cardiol TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The constructive case is that MAVERIC enrollment is advancing, Phase II data have gained peer-reviewed validation support, and the company says it is funded through completion of the pivotal trial, allowing investors to focus on the next clinical milestone rather than near-term survival financing [#PR-2026-04-01] [#PR-EARNINGS-2026-05-07].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
CRD-38 is still an earlier-stage secondary program, so pipeline diversification is not yet strong enough to offset lead-program dependency.
Momentum
91
Value
41
Sentiment
29
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.95 · Bull $1.80 · Bear $0.50
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $6.92
Why
Momentum91 · Δ7d -
Value41 · Δ7d +0.0
Sentiment29 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
29
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 91.0 / Value 41.1 / Sentiment 28.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$144.32M
Beta
0.84
Shares Out
115.27M
P/E (TTM) · Derived
-4.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.65
Rev YoY
-100.0%
EPS YoY
+3.6%
Gross Margin
-
Op Margin
-
Net Debt
-$15.53M
Current Ratio
4.39
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology